Costos directos en el tratamiento del pie diabético Unidad de Pie Diabético. Hospital de Clínicas. Universidad de la República

Pablo Orellano; Luciana Sánchez; Lucía Introini; Wendy Torre; Matías Torres Negreira; Marta Cabrera; Pedro Bisensang; Lilián Vucovich

doi:10.29193/RMU.39.4.2

Authors

Pablo Orellano Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Unidad de Pie Diabético, Endocrinología y Metabolismo, Ex Prof. Adj. https://orcid.org/0000-0002-5080-5961
Luciana Sánchez Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Endocrinología y Metabolismo, Especialista https://orcid.org/0000-0003-2600-3499
Lucía Introini Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Unidad de Pie Diabético, Posgrado de Endocrinología y Metabolismo https://orcid.org/0000-0002-7488-3876
Wendy Torre Universidad de la República, Facultad de Medicina, Unidad de Pie Diabético, Carrera de Podología EUTM, Asistente https://orcid.org/0000-0002-4088-4766
Matías Torres Negreira Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Endocrinología y Metabolismo, Especialista https://orcid.org/0000-0003-1098-3680
Marta Cabrera Universidad de la República, Facultad de Medicina, Unidad de Pie Diabético, Carrera de Podología EUTM, Prof. Adj. https://orcid.org/0000-0001-6615-465X
Pedro Bisensang Universidad de la República, Facultad de Medicina, Unidad de Pie Diabético, Carrera de Podología EUTM, Asistente https://orcid.org/0000-0003-0367-6420
Lilián Vucovich Universidad de la República, Facultad de Medicina, Unidad de Pie Diabético, Carrera de Podología EUTM, Directora, Prof. Agrdo. https://orcid.org/0000-0002-0801-8649

DOI:

https://doi.org/10.29193/RMU.39.4.2

Keywords:

DIABETES MELLITUS, DIABETIC FOOT, DIABETIC FOOT ULCER, AMPUTATION, COST ANALYSIS

Abstract

On a global scale, a diabetic patient incurs healthcare expenses that are 2 to 3 times higher than those of a non-diabetic individual. Diabetic foot syndrome reduces the quality of life, increases morbidity and mortality, and places an economic burden on the healthcare system.
Objective: Communicating the research conducted on direct costs in the treatment of diabetic foot ulcers.
Method: Observational, descriptive, retrospective study of patients treated at the Foot Unit of the Hospital de Clínicas (UDELAR) between October 2014 and September 2016. Direct treatment costs for outpatient care and hospitalization were estimated using information from the medical records. The treatment horizon extended over a period of 3 months. Expenses were calculated in readjustable units, Uruguayan pesos (UYU), and United States dollars (USD). Expenses were updated to October 2022 using the Consumer Price Index (IPC) adjusted for the cumulative inflation rate.
Results: 49 patients were included in the study: 11 women and 38 men, average age was 61.5 years old. The overall expenditure exceeded 400,000 USD, with the highest cost attributed to hospitalization expenses. The average total expenditure per patient amounted to 8,799 USD. The cost of conventional treatment was 3,707.93 USD, major amputation represented USD 32,003.61, and minor amputation USD 12,385.34. Hospitalization expenses significantly exceeded those of outpatient care. In the emergency department, 28 patients spent USD 4,396. The increase in costs by the year 2022 amounted to 37.45%, resulting in a total expenditure of UYU 16,682,993.4 (Uruguayan pesos) or USD 410,830.2.
Conclusions: It was the first assessment in our country to estimate diabetic foot costs. The cost of ulcer management imposes a significant and increasing economic burden.
The initial severity of the ulcer results in hospitalization which implies high associated costs.
Hospitalization and amputation costs constitute the most substantial economic expenditure.

References

Magliano DJ, Boyko EJ, Balkau B, Barengo N, Barr E, Basit A, et al. IDF diabetes Atlas 2021. 10th ed. Brussels: International Diabetes Federation, 2021. Disponible en: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf (Consulta: 21 julio 2022).

Sandoya E. Diabetes y enfermedad cardiovascular en Uruguay. Rev Urug Cardiol 2016; 31:505-14. Disponible en: http://www.scielo.edu.uy/pdf/ruc/v31n3/v31n3a12.pdf (Consulta: 24 marzo 2023).

Ferrero R, García MV. Encuesta de prevalencia de la diabetes en Uruguay. Primera fase: Montevideo año 2004. Arch Med Int 2005; 27(1):7-12.

Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376(24):2367-75. doi: 10.1056/NEJMra1615439.

Huang ZH, Li SQ, Kou Y, Huang L, Yu T, Hu A. Risk factors for the recurrence of diabetic foot ulcers among diabetic patients: a meta-analysis. Int Wound J 2019; 16(6):1373-82. doi: 10.1111/iwj.13200.

Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res 2020; 13(1):16. doi: 10.1186/s13047-020-00383-2.

Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab 2018; 9(1):29-31. doi: 10.1177/2042018817744513.

Skrepnek GH, Mills JL, Armstrong DG. A diabetic emergency one million feet long: disparities and burdens of Illness among diabetic foot ulcer cases within emergency departments in the United States, 2006–2010. PloS One 2015; 10(8):e0134914. doi: 10.1371/journal.pone.0134914.

Carls GS, Gibson TB, Driver VR, Wrobel JS, Garoufalis MG, Defrancis RR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc 2011; 101(2):93-115. doi: 10.7547/1010093.

Montiel-Jarquín ÁJ, García Villaseñor A, Castillo Rodríguez C, Romero-Figueroa MS, Etchegaray-Morales I, García-Cano E, et al. Costes directos de atención médica del pie diabético en el segundo nivel de atención médica. Rev Chil Cir 2017; 69(2):118-23. doi: 10.1016/j.rchic.2016.09.009.

Arredondo A, De Icaza E. Costos de la diabetes en América Latina: evidencias del caso Mexicano. Value Health 2011; 14(5 Suppl 1):S85-S88. doi: 10.1016/j.jval.2011.05.022.

Toscano CM, Sugita TH, Rosa MQM, Pedrosa HC, Rosa RDS, Bahia LR. Annual direct medical costs of diabetic foot disease in Brazil: a cost of illness study. Int J Environ Res Public Health 2018; 15(1):89. doi: 10.3390/ijerph15010089.

Cárdenas MK, Mirelman AJ, Galvin CJ, Lazo-Porras M, Pinto M, Miranda JJ, et al. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru. BMC Health Serv Res 2015; 15:483. doi: 10.1186/s12913-015-1141-4.

Oliveira AF, De Marchi AC, Leguisamo CP, Baldo GV, Wawginiak TA. Estimativa do custo de tratar o pé diabético, como prevenir e economizar recursos. Ciên Saúde Colet 2014; 19(6):1663-71. doi: 10.1590/1413-81232014196.09912013.

Ripari N, Moscoso N, Elorza M. Costos de enfermedades: una revisión crítica de las metodologías de estimación. Lect Econ 2012; (77):253-82. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-25962012000200008&lng=es&nrm=iso&tlng=es (Consulta: 3 setiembre 2022).

Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl 1):e3280. doi: 10.1002/dmrr.3280.

Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Fitridge R, Game F, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev 2023:e3657. doi: 10.1002/dmrr.3657.

Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981; 2(2):64-122. doi: 10.1177/107110078100200202.

Uruguay. Ministerio de Economía y Finanzas. Unidad Centralizada de Adquisiciones. Antecedentes. Disponible en: https://www.mef.gub.uy/10436/13/areas/antecedentes.html (Consulta: 24 marzo 2023).

Dirección Nacional de Impresiones y Publicaciones Oficiales. Valores fijados para la UR, URA y CRA (período 2023 - 1974). Disponible en: http://impo.com.uy/valores (Consulta: 27 marzo 2023).

Uruguay. Instituto Nacional de Estadística. Unidad reajustable. Disponible en: http://www.ine.gub.uy/unidad-reajustable. (Consulta: 15 setiembre 2023).

Mercadeo de multinivel: marketing para emprendedores. Magazine digital del Prof. José Sotelo. Unidad Reajustable: ¿Qué es y para qué se usa?. Disponible en: https://mercadeodemultinivel.wordpress.com/2009/06/06/unidad-reajustable-%c2%bfque-es-y-para-que-se-usa/ (Consulta: 15 setiembre 2023).

Uruguay. Instituto Nacional de Estadística. Cotización de monedas. Disponible en: https://www.gub.uy/instituto-nacional-estadistica/datos-y-estadisticas/estadisticas/cotizacion-monedas (Consulta: 24 marzo 2023).

Uruguay. Ministerio de Economía y Finanzas. Dirección General Impositiva. Disponible en: https://www.dgi.gub.uy/wdgi/page?2,principal,ampliacion- DatosSeresEstadisticas,O,es,0,PAG;CONC;937;9;D;unidad-reajustable-ur;92;PAG; (Consulta: 24 setiembre 2022).

Uruguay. Banco Central del Uruguay. Cotización de monedas. Disponible en: https://www.bcu.gub.uy/Estadisticas-e-Indicadores/Paginas/Cotizaciones.aspx (Consulta: 27 marzo 2023).

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50(1):18-25. doi: 10.1007/s00125-006-0491-1.

Kerr M. Diabetic foot care in England: an economic study. 2017. Disponible en: https://www.diabetes.org.uk/professionals/resources/sharedpractice/footcare (Consulta: 26 octubre 2022).

Monami M, Ragghianti B, Nreu B, Lorenzoni V, Pozzan M, Silverii A, et al. Major amputation in non-healing ulcers: outcomes and economic issues. Data from a cohort of patients with diabetic foot ulcers. Int J Low Extrem Wounds 2022:15347346221097283. doi: 10.1177/15347346221097283.

Ibarra A. Prevalencia y características clínicas de pacientes diabéticos ingresados en un hospital general. Arch Med Int 2015; 37(2):57-60. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-423X2015000200002&lng=es (Consulta: 9 julio 2022).

Toscano CM, Sugita TH, Rosa MQM, Pedrosa HC, Rosa RDS, Bahia LR. Annual direct medical costs of diabetic foot disease in Brazil: a cost of illness study. Int J Environ Res Public Health 2018; 15(1):89. doi: 10.3390/ijerph15010089.

Schaper NC. Lessons from Eurodiale. Diabetes Metab Res Rev 2012; 28(Suppl 1):21-6. doi: 10.1002/dmrr.2266.

Armstrong DG, Kanda VA, Lavery LA, Marston W, Mills JL, Boulton AJ. Mind the gap: disparity between research funding and costs of care for diabetic foot ulcers. Diabetes Care 2013; 36(7):1815-7. doi: 10.2337/dc12-2285.

Ragnarson Tennvall G, Apelqvist J. Health-Economic consequences of diabetic foot lesions. Clin Infect Dis 2004; 39 (Suppl 2):S132-S139. doi: 10.1086/383275.

Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab 2018; 9(1):29-31. doi: 10.1177/2042018817744513.

Girod I, Valensi P, Laforêt C, Moreau-Defarges T, Guillon P, Baron F. An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients. Diabetes Metab 2003; 29(3):269-77. doi: 10.1016/s1262-3636(07)70036-8.

Bus SA, Armstrong DG, Gooday C, Jarl G, Caravaggi C, Viswanathan V, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl 1):e3274. doi: 10.1002/dmrr.3274.

Fernando ME, Horsley M, Jones S, Martin B, Nube VL, Charles J, et al. Australian guideline on offloading treatment for foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. J Foot Ankle Res 2022; 15(1):31. doi: 10.1186/s13047-022-00538-3.

Lu Q, Wang J, Wei X, Wang G, Xu Y, Lu Z, et al. Cost of diabetic foot ulcer management in China: a 7-year single-center retrospective review. Diabetes Metab Syndr Obes 2020; 13:4249-60. doi: 10.2147/DMSO.S275814.

Ferre Z, Gerstenblüth M, González C, Noboa C, Triunfo P. Salud y acceso a cuidados médicos durante la pandemia en Uruguay. Rev Méd Urug 2021; 37(3):e206. doi: 10.29193/RMU.37.3.6.

American Medical Association. Robeznieks A. Physician survey details the depth of the financial impact of the pandemic American Medical Association. October 28, 2020. Disponible en: https://www.ama-assn.org/practice-management/sustainability/physician-survey-details-depth-pandemic-s-financial-impact (Consulta: 24 setiembre 2022).

Caruso P, Longo M, Signoriello S, Gicchino M, Maiorino MI, Bellastella G, et al. Diabetic foot problems during the COVID-19 pandemic in a tertiary care center: the emergency among the emergencies. Diabetes Care 2020; 43(10):e123-e124. doi: 10.2337/dc20-1347.

Pradines L, García L, Bruno L, Filomeno P. La Unidad de Pie Diabético del Hospital Pasteur: modelo de atención y pautas de actuación: importancia del abordaje interdisciplinario. Montevideo: Cuadrado, 2023.

National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. London: NICE, 2015. Disponible en: https://www.nice.org.uk/guidance/ng19/resources/diabetic-foot-problems-prevention-and-management-pdf-1837279828933 (Consulta: 24 setiembre 2022).

Monteiro-Soares M, Russell D, Boyko EJ, Jeffcoate W, Mills JL, Morbach S, et al. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). Diabetes Metab Res Rev 2020; 36(Suppl 1):e3273. doi: 10.1002/dmrr.3273.

Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. Int Wound J 2017; 14(4):616-28. doi: 10.1111/iwj.12653.

Fortuna C, Giaudrone I, Saucedo Á, Scópice R, Silva L, Silveira J, et al. Calidad de vida en pacientes diabéticos amputados menores de 60 años en Hospital Pasteur, Uruguay. En el período de agosto - setiembre de 2018. Anafamed 2021; 8(S1). Disponible en: https://revistas.udelar.edu.uy/OJS/index.php/anfamed/article/view/458/449 (Consulta: 24 setiembre 2022).

National Cancer Institute. NCI Budget and Appropriations. 2015. Disponible en: https://www. cancer.gov/about-nci/budget (Consulta: 24 setiembre 2022).

Lavery LA, Hunt NA, Ndip A, Lavery DC, Van Houtum W, Boulton AJ. Impact of chronic kidney disease on survival after amputation in individuals with diabetes. Diabetes Care 2010; 33(11):2365-9. doi: 10.2337/dc10-1213.